Key opinion leaders discuss how bispecifics are administered at their institutions.
Data Support Real-World Use of Ide-cel in R/R CNS Multiple Myeloma
Real-world data show that CAR T-cell therapy may be considered for eligible patients with relapsed/refractory multiple myeloma harboring CNS involvement.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
Overall MRD Negativity Rates Improved with Cilta-cel vs SOC in MM
In patients with lens-refractory multiple myeloma, cilta-cel generated deeper minimal residual disease rates across all patient subgroups.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Superior Rates of MRD Upheld by Isatuximab Combo in Multiple Myeloma
Patients with newly diagnosed multiple myeloma experienced sustained MRD negativity with isatuximab/bortezomib/lenalidomide/dexamethasone.
Belantamab Mafodotin Regimen Improves OS in R/R Multiple Myeloma
Findings from DREAMM-7 support belantamab mafodotin plus bortezomib and dexamethasone as a standard of care in relapsed/refractory multiple myeloma.
